Piper Sandler Has Lowered Expectations for Dyne Therapeutics (NASDAQ:DYN) Stock Price

Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by Piper Sandler from $53.00 to $48.00 in a research report released on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

DYN has been the subject of a number of other research reports. HC Wainwright reduced their price target on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating for the company in a research report on Friday. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 price target on the stock. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $48.64.

Dyne Therapeutics Trading Up 3.3 %

DYN opened at $13.61 on Friday. The stock has a market capitalization of $1.39 billion, a P/E ratio of -3.82 and a beta of 1.11. Dyne Therapeutics has a 12 month low of $12.87 and a 12 month high of $47.45. The firm’s fifty day simple moving average is $16.98 and its 200 day simple moving average is $27.73.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, equities research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the sale, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,387 shares of company stock worth $142,789 over the last 90 days. Company insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the third quarter worth approximately $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics in the 3rd quarter valued at $36,000. US Bancorp DE increased its position in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $50,000. Finally, KBC Group NV grew its stake in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after acquiring an additional 978 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.